Trials / Recruiting
RecruitingNCT07321873
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-88545223 For the Treatment of Participants With Active Psoriatic Arthritis
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate how well the study drug JNJ-88545223 works compared with a placebo (an inactive substance) in adults with active psoriatic arthritis (PsA). The study aims to see whether treatment with JNJ-88545223 can help reduce the signs and symptoms of PsA and improve joint and skin health.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-88545223 | JNJ-88545223 will be administered orally. |
| DRUG | Placebo | Placebo will be administered orally. |
Timeline
- Start date
- 2026-01-15
- Primary completion
- 2027-06-28
- Completion
- 2027-08-02
- First posted
- 2026-01-07
- Last updated
- 2026-04-13
Locations
40 sites across 6 countries: United States, China, Germany, Japan, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07321873. Inclusion in this directory is not an endorsement.